Bullish Moving Averages
2
Bearish Moving Averages
14
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul
Performance
Today’s low
480.20Today’s High
491.7052W low
431.0052W High
635.00Open Price
486.60Prev. Close
484.0500Volume
69203.00Value
33542694.10Fundamentals
Market Cap
4423.90
Price to Earnings
29.10
Price to Book Value
3.50
Dividend Yield
0.20
PE to Growth
-1.90
Op Revenue TTM
2379.60
Net Profit TTM
152.23
Cash From Operating Activity
358.92
Return on Equity %
13.37
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
30 Oct, 2024
47.1
Week
41.3
Month
46.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
485.52
PIVOT
First Resistance
490.88
Second Resistance
497.07
Third Resistance
502.43
First Support
479.33
Second Support
473.97
Third Support
467.78
Relative Strength Index
33.15
Money Flow Index
26.63
MACD
-11.51
MACD Signal
-10.7
Average True Range
12.64
Average Directional Index
22.93
Rate of Change (21)
-5.55
Rate of Change (125)
-3.21
Day Commodity Channel Index
-80.3
William
-61.53
BETA
1 Month
0.77
3 Month
0.72
1 Year
0.66
3 Year
0.43
PRICE CHANGE ANALYSIS
↓ -0.8%
1 Week
Low
High
466.1
492
↓ -5.76%
1 Month
Low
High
466.1
529
↓ -3.69%
3 Months
Low
High
466.1
635
↓ -4.41%
6 Months
Low
High
451.05
635
↑ 2.9%
1 Year
Low
High
431.05
635
| Indicator | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 543.47 | 493.07 | 560.64 | 539.89 | 578.28 | 592.29 | 697.34 | 626.50 | 624.92 | 551.44 | 642.10 | 594.83 | 511.59 | |
| Operating Expenses Qtr | 483.55 | 438.74 | 490.47 | 478.47 | 512.12 | 519.73 | 607.89 | 556.55 | 554.65 | 496.47 | 557.38 | 502.53 | 441.56 | |
| Operating Profit Qtr | 59.54 | 54.22 | 69.06 | 59.74 | 65.42 | 71.90 | 88.52 | 68.98 | 70.18 | 54.73 | 84.10 | 90.68 | 69.14 | |
| EBIDT Qtr Cr | 59.92 | 54.33 | 70.17 | 61.42 | 66.16 | 72.56 | 89.45 | 69.95 | 70.27 | 54.97 | 84.72 | 92.30 | 70.03 | |
| Depreciation Qtr | 11.86 | 11.71 | 12.34 | 11.80 | 11.78 | 11.75 | 11.68 | 11.87 | 11.92 | 11.83 | 11.88 | 11.95 | 11.81 | |
| Net Profit Qtr | 30.39 | 26.91 | 36.14 | 31.62 | 34.58 | 39.54 | 53.17 | 36.71 | 36.58 | 26.35 | 53.00 | 55.85 | 40.61 | |
| Basic EPS Qtr | 3.33 | 2.93 | 3.93 | 3.44 | 3.75 | 4.27 | 5.74 | 3.96 | 3.95 | 2.85 | 5.72 | 6.03 | 4.39 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 2271.09 | 2500.20 | 2255.95 | 1921.31 | 1635.98 | |
| Operating Expenses Annual Cr | 2000.78 | 2215.57 | 1932.99 | 1513.62 | 1390.51 | |
| Operating Profit Annual | 266.13 | 282.40 | 318.18 | 401.27 | 244.41 | |
| Operating Profit Margin Annual % | 11.72 | 11.30 | 14.10 | 20.89 | 14.94 | |
| Total Expenses Annual Cr | 2078.61 | 2295.39 | 2000.45 | 1583.83 | 1469.39 | |
| EBIDT Annual Cr | 270.31 | 284.64 | 322.96 | 407.69 | 245.47 | |
| EBIDT Annual margin % | 11.90 | 11.38 | 14.32 | 21.22 | 15.00 | |
| Depreciation | 47.67 | 47.29 | 47.39 | 47.60 | 46.67 | |
| PAT Before ExtraOrdinary Items Annual Cr | 141.88 | 152.81 | 195.00 | 257.71 | 135.67 | |
| Net Profit Annual | 141.88 | 152.81 | 195.00 | 257.71 | 135.67 | |
| Basic EPS Annual | 15.35 | 16.50 | 21.04 | 27.65 | 58.12 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 1175.21 | 1114.30 | 972.17 | 859.61 | 621.79 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 311.81 | 250.20 | 207.67 | 255.50 | 292.91 | |
| Total Current Liabilities Annual Cr | 684.60 | 830.99 | 854.68 | 521.89 | 555.99 | |
| Total Capital Plus Liabilities Annual Cr | 2171.62 | 2195.50 | 2034.52 | 1637.01 | 1470.70 | |
| Fixed Assets Annual | 943.92 | 795.23 | 709.03 | 646.47 | 622.53 | |
| Total Non Current Assets Annual | 990.60 | 845.96 | 761.33 | 676.88 | 645.33 | |
| Total Current Assets Annual | 1181.02 | 1349.53 | 1273.19 | 960.13 | 825.36 | |
| Total Assets Annual | 2171.62 | 2195.50 | 2034.52 | 1637.01 | 1470.70 | |
| Contingent Liabilities plus Commitments Annual Cr | 266.61 | 258.17 | 194.24 | 152.85 | 89.82 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 337.10 | 162.28 | 39.90 | 154.08 | 196.15 | |
| Cash from Investing Activity Annual | -187.09 | -131.14 | -125.36 | -68.93 | -29.35 | |
| Cash from Financing Annual Activity | -148.81 | -30.54 | 84.11 | -85.28 | -167.76 | |
| Net Cash Flow Annual | 1.20 | 0.61 | -1.35 | -0.13 | -0.96 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 127.83 | 120.33 | 104.99 | 92.23 | 266.86 | |
| ROE Annual % | 12.07 | 13.71 | 20.05 | 29.98 | 21.82 | |
| ROCE Annual % | 14.97 | 17.39 | 23.35 | 32.29 | 21.73 | |
| Total Debt to Total Equity Annual | 0.40 | 0.48 | 0.53 | 0.34 | 0.53 | |
| EBDIT Annual Margin % | 11.92 | 11.39 | 14.34 | 21.29 | 15.01 |
| Indicator | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 599.81 | 556.45 | 621.07 | 607.61 | 642.23 | 661.71 | 743.28 | 664.97 | 687.77 | 622.22 | 697.23 | 641.46 | 579.70 | |
| Operating Expenses Qtr | 531.28 | 490.38 | 534.18 | 535.80 | 565.10 | 577.03 | 648.87 | 593.31 | 613.45 | 554.82 | 608.27 | 544.80 | 505.88 | |
| Operating Profit Qtr | 67.05 | 64.96 | 85.81 | 70.14 | 76.44 | 84.08 | 93.54 | 70.65 | 74.27 | 67.14 | 86.00 | 90.00 | 73.74 | |
| EBIDT Qtr Cr | 68.53 | 66.07 | 86.89 | 71.81 | 77.13 | 84.68 | 94.41 | 71.66 | 74.32 | 67.40 | 88.96 | 96.66 | 73.82 | |
| Depreciation Qtr | 13.72 | 13.38 | 13.58 | 12.66 | 12.61 | 12.60 | 12.50 | 12.62 | 12.66 | 12.54 | 12.55 | 12.60 | 12.48 | |
| Net Profit Qtr | 35.01 | 33.24 | 47.31 | 36.67 | 39.59 | 47.85 | 56.09 | 36.68 | 38.75 | 34.79 | 55.32 | 58.28 | 42.58 | |
| Basic EPS Qtr | 3.83 | 3.62 | 5.15 | 3.99 | 4.29 | 5.18 | 6.07 | 3.96 | 4.18 | 3.76 | 5.97 | 6.29 | 4.60 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 2532.61 | 2718.25 | 2499.96 | 2159.30 | 1807.57 | |
| Operating Expenses Annual Cr | 2212.12 | 2410.45 | 2159.21 | 1717.67 | 1544.27 | |
| Operating Profit Annual | 316.46 | 305.61 | 329.44 | 437.10 | 261.82 | |
| Operating Profit Margin Annual % | 12.50 | 11.24 | 13.18 | 20.24 | 14.48 | |
| Total Expenses Annual Cr | 2297.08 | 2494.07 | 2230.01 | 1790.52 | 1626.75 | |
| EBIDT Annual Cr | 320.49 | 307.80 | 340.75 | 441.63 | 263.30 | |
| EBIDT Annual margin % | 12.65 | 11.32 | 13.63 | 20.45 | 14.57 | |
| Depreciation | 51.45 | 50.32 | 50.05 | 49.88 | 48.75 | |
| PAT Before ExtraOrdinary Items Annual Cr | 171.59 | 166.36 | 205.00 | 280.40 | 141.40 | |
| Net Profit Annual | 171.42 | 166.31 | 205.04 | 280.41 | 141.40 | |
| Basic EPS Annual | 18.56 | 17.97 | 22.12 | 30.09 | 60.57 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 1281.55 | 1192.43 | 1036.36 | 913.42 | 652.49 | |
| Minority Interest Liability Annual Cr | 0.41 | 0.23 | -0.06 | -0.02 | -0.00 | |
| Total Non Current Liabilities Annual Cr | 354.86 | 295.75 | 231.60 | 257.25 | 299.31 | |
| Total Current Liabilities Annual Cr | 795.54 | 932.98 | 940.06 | 595.36 | 624.70 | |
| Total Capital Plus Liabilities Annual Cr | 2432.36 | 2421.40 | 2207.96 | 1766.01 | 1576.50 | |
| Fixed Assets Annual | 1071.96 | 886.58 | 766.67 | 684.66 | 656.02 | |
| Total Non Current Assets Annual | 1111.64 | 929.05 | 814.59 | 709.22 | 672.50 | |
| Total Current Assets Annual | 1320.72 | 1492.35 | 1393.37 | 1056.80 | 904.00 | |
| Total Assets Annual | 2432.36 | 2421.40 | 2207.96 | 1766.01 | 1576.50 | |
| Contingent Liabilities plus Commitments Annual Cr | 281.02 | 262.94 | 211.49 | 155.67 | 92.06 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 358.92 | 134.20 | 69.64 | 154.85 | 250.74 | |
| Cash from Investing Activity Annual | -223.65 | -163.97 | -148.86 | -71.68 | -33.21 | |
| Cash from Financing Annual Activity | -136.03 | 16.54 | 92.03 | -81.13 | -215.41 | |
| Net Cash Flow Annual | -0.76 | -13.23 | 12.80 | 2.04 | 2.13 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 139.40 | 128.77 | 111.91 | 98.00 | 280.04 | |
| ROE Annual % | 13.37 | 13.94 | 19.78 | 30.69 | 21.67 | |
| ROCE Annual % | 16.43 | 17.29 | 22.92 | 33.46 | 22.54 | |
| Total Debt to Total Equity Annual | 0.44 | 0.51 | 0.52 | 0.33 | 0.52 | |
| EBDIT Annual Margin % | 12.67 | 11.33 | 13.69 | 20.49 | 14.57 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Prakash Moreshwar Patil | 9.23 | 103622965 | 0 | 0 |
| Harshit Manilal Savla | 4.74 | 103622966 | 0 | 0 |
| Rashesh Chandrakant Gogri | 4.64 | 103622967 | 0 | 0 |
| Priti Prakash Patil | 4.4 | 103622968 | 0 | 0 |
| Seema Harshit Savla | 3.84 | 103622969 | 0 | 0 |
| Hetal Gogri Gala | 3.05 | 103622970 | 0 | 0 |
| Chandrakant Vallabhaji Gogri | 1.87 | 103622971 | 0 | 0 |
| Jaya Chandrakant Gogri | 1.71 | 103622972 | 0 | 0 |
| Adhish P. Patil | 1.24 | 103622973 | 0 | 0 |
| Bhoomi Harshit Savla | 1.09 | 103622974 | 0 | 0 |
| Vishwa Harshit Savla | 1.03 | 103622975 | 0 | 0 |
| Aashay Rashesh Gogri | 0.96 | 103622976 | 0 | 0 |
| Mirik Rajendra Gogri | 0.8 | 103622977 | 0 | 0 |
| Renil Rajendra Gogri | 0.8 | 103622978 | 0 | 0 |
| Gogri Finserv Pvt. Ltd. | 3.8 | 103622996 | 0 | 0 |
| Anushakti Enterprise Private Limited | 2.62 | 103622997 | 0 | 0 |
| Alchemie Finserv Pvt. Ltd. | 2.21 | 103622998 | 0 | 0 |
| Aashyav Business Trust (Alabhya Trusteeship Private Limited) | 1.5 | 103622999 | 0 | 0 |
| Tulip Family Trust (Gloire Trusteeship Services Private Limited) | 1.01 | 103623000 | 0 | 0 |
| Orchid Family Trust (Relacion Trusteeship Services Private Limited) | 0.99 | 103623001 | 0 | 0 |
| Paridhi Business Trust (Saswat Trusteeship Private Limited) | 0.64 | 103623002 | 0 | 0 |
| Safechem Enterprises Private Limited | 0.61 | 103623003 | 0 | 0 |
| Dilesh Roadlines Pvt Ltd | 0.54 | 103623004 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| Dsp Small Cap Fund | 5.93 | 103623010 |
| Blend Fund 2 | 1.14 | 103623013 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HUF | 0.73 | 103623019 |
| Harit Pragji Shah | 2.67 | 103623030 |
| Jayshree Harit Shah | 1.79 | 103623031 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Feb 06, 2024 | 1 | INTERIM | Feb 06, 2024 | Equity Share |
| Feb 08, 2023 | 1 | INTERIM | Feb 08, 2023 | Equity Share |
| Feb 09, 2022 | 1 | INTERIM | Feb 10, 2022 | Equity Share |
| Nov 03, 2020 | 2.5 | INTERIM | Nov 04, 2020 | Equity Share |
| Feb 17, 2020 | 2 | INTERIM | Feb 18, 2020 | Equity Share |
| Jul 26, 2019 | 1 | FINAL | - | Equity Share |
| Aug 01, 2018 | 1 | FINAL | - | Equity Share |
| Aug 09, 2017 | 1 | FINAL | - | Equity Share |
| Mar 22, 2016 | 3 | INTERIM | Mar 24, 2016 | Equity Share |
| Feb 12, 2016 | 1.5 | INTERIM | Feb 15, 2016 | Equity Share |
| Nov 10, 2015 | 2.25 | INTERIM | Nov 14, 2015 | Equity Share |
| Aug 05, 2015 | 3 | FINAL | - | Equity Share |
| Feb 04, 2015 | 5 | INTERIM | Feb 05, 2015 | Equity Share |
| Nov 19, 2014 | 5 | INTERIM | Nov 20, 2014 | Equity Share |
| Jul 02, 2014 | 5.5 | FINAL | - | Equity Share |
| Feb 05, 2014 | 4.5 | INTERIM | Feb 06, 2014 | Equity Share |
| Nov 19, 2013 | 3 | INTERIM | Nov 20, 2013 | Equity Share |
| Jul 24, 2013 | 4 | FINAL | - | Equity Share |
| Feb 11, 2013 | 3 | INTERIM | Feb 12, 2013 | Equity Share |
| Nov 05, 2012 | 3 | INTERIM | Nov 06, 2012 | Equity Share |
| Aug 17, 2012 | 3 | FINAL | - | Equity Share |
| Feb 06, 2012 | 2 | INTERIM | Feb 07, 2012 | Equity Share |
| Jul 14, 2011 | 2.5 | FINAL | - | Equity Share |
| Feb 07, 2011 | 2.5 | INTERIM | Feb 08, 2011 | Equity Share |
| Aug 18, 2010 | 5 | FINAL | - | Equity Share |
| Jul 23, 2009 | 3 | FINAL | - | Equity Share |
| Aug 13, 2008 | 1.8 | FINAL | - | Equity Share |
| Mar 20, 2007 | 1.2 | INTERIM | Mar 21, 2007 | Equity Share |
| Jul 19, 2006 | 1.5 | FINAL | - | Equity Share |
| Jul 27, 2005 | 1.6 | FINAL | - | Equity Share |
| Nov 04, 2004 | 1.4 | INTERIM | Nov 06, 2004 | Equity Share |
| Jun 25, 2004 | 1.8 | FINAL | - | Equity Share |
| Nov 13, 2003 | 1.2 | INTERIM | Nov 15, 2003 | Equity Share |
| Jul 25, 2003 | 1.5 | FINAL | - | Equity Share |
| Jun 20, 2002 | - | FINAL | - | Equity Share |
| Oct 23, 2001 | - | INTERIM | Nov 08, 2001 | Equity Share |
| Jun 11, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| Oct 24, 2024 | Quarterly Results | - |
| Aug 26, 2024 | Buy Back of Shares | - |
| Jul 26, 2024 | Quarterly Results | - |
| May 03, 2024 | Audited Results | - |
| Jan 24, 2024 | Quarterly Results & Interim Dividend | - |
| Oct 19, 2023 | Quarterly Results | - |
| Jul 21, 2023 | Quarterly Results & Buy Back | - |
| Apr 29, 2023 | Audited Results | - |
| Jan 27, 2023 | Quarterly Results & Interim Dividend | - |
| Oct 20, 2022 | Quarterly Results | - |
| Jul 27, 2022 | Quarterly Results | - |
| May 09, 2022 | Audited Results | - |
| Jan 31, 2022 | Audited Results & Interim Dividend | - |
| Oct 27, 2021 | Quarterly Results | - |
| Jul 27, 2021 | Quarterly Results | - |
| May 15, 2021 | Audited Results | - |
| Mar 19, 2021 | Buy Back of Shares | - |
| Jan 25, 2021 | Quarterly Results | - |
| Oct 23, 2020 | Audited Results | - |
| Oct 20, 2020 | Audited Results & Interim Dividend | - |
| Aug 20, 2020 | Bonus issue | - |
| Jul 25, 2020 | Quarterly Results | - |
| May 15, 2020 | Audited Results | - |
| Feb 06, 2020 | Quarterly Results & Interim Dividend | - |
| Oct 23, 2019 | Audited Results | - |
| Jul 26, 2019 | Quarterly Results | - |
| May 15, 2019 | Audited Results & Final Dividend | - |
| Mar 15, 2019 | Buy Back of Shares | - |
| Feb 11, 2019 | Quarterly Results | - |
| Nov 02, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Quarterly Results | - |
| May 16, 2018 | Audited Results & Final Dividend | - |
| Feb 13, 2018 | Quarterly Results | - |
| Jan 08, 2018 | Buy Back of Shares | - |
| Nov 13, 2017 | Quarterly Results | - |
| Aug 18, 2017 | Quarterly Results | - |
| May 23, 2017 | Audited Results & Final Dividend | - |
| Feb 08, 2017 | Quarterly Results | - |
| Nov 09, 2016 | Quarterly Results | - |
| Oct 17, 2016 | Buy Back of Shares | - |
| Aug 12, 2016 | Quarterly Results | - |
| May 05, 2016 | Audited Results | - |
| Mar 16, 2016 | 3rd Interim Dividend | - |
| Feb 05, 2016 | Quarterly Results & 2nd Interim Dividend | - |
| Nov 06, 2015 | Quarterly Results & Interim Dividend | - |
| Jul 31, 2015 | Quarterly Results | - |
| May 20, 2015 | Audited Results & Final Dividend | - |
| Mar 26, 2015 | Others | To consider & approve the allotment of 121,08,550 Equity shares as Bonus issue in the proportion of 1 new equity share for every 1 (One) existing fully paid equity shares. |
| Jan 30, 2015 | Quarterly Results & Interim Dividend | Second Interim Dividend |
| Nov 14, 2014 | Quarterly Results & Interim Dividend | - |
| Aug 08, 2014 | Quarterly Results | - |
| Apr 30, 2014 | Audited Results & Final Dividend | - |
| Jan 31, 2014 | Quarterly Results & 2nd Interim Dividend | - |
| Nov 14, 2013 | Quarterly Results & Interim Dividend | - |
| Aug 02, 2013 | Quarterly Results | - |
| May 16, 2013 | Audited Results & Final Dividend | - |
| Feb 06, 2013 | Quarterly Results & Interim Dividend | - |
| Oct 31, 2012 | Quarterly Results & Interim Dividend | - |
| Aug 10, 2012 | Quarterly Results | - |
| Jul 09, 2012 | Audited Results | Inter alia, to reconsider, approve and take on record the Audited Financial Results for the year ended March 31, 2012, post amalgamation of Suyash Laboratories Ltd. with the Company. |
| May 25, 2012 | Audited Results & Final Dividend | - |
| Feb 09, 2012 | Others | The Board has consider the Sucession Plan post retirement of Shri. Chandrakant V Gogri as the Chairman of the Company w.e.f August 16, 2012 on his attaining the age of 66 years. |
| Feb 01, 2012 | Quarterly Results & Interim Dividend | - |
| Nov 11, 2011 | Quarterly Results | - |
| Jul 29, 2011 | Quarterly Results | - |
| May 25, 2011 | Audited Results & Final Dividend | - |
| Feb 02, 2011 | Quarterly Results & Interim Dividend | - |
| Oct 29, 2010 | Quarterly Results | - |
| Jul 30, 2010 | Quarterly Results | - |
| May 26, 2010 | Audited Results & Dividend | - |
| Jan 25, 2010 | Quarterly Results | - |
| Dec 20, 2009 | Allotment of Equity Shares | The Board has allotted 4,00,000 Equity Shares of Rs. 10/- each fully paid up against exercise of option of Conversion by the holders of Conv. Warrants issued by the Company on preferential basis. |
| Oct 30, 2009 | Quarterly Results | - |
| Jul 30, 2009 | Quarterly Results | - |
| May 20, 2009 | Audited Results & Dividend | - |
| Jan 29, 2009 | Quarterly Results | (Revised) |
| Oct 20, 2008 | Quarterly Results | - |
| Aug 06, 2008 | To call an EGM & Others | To consider: Allotment of one Equity share of Rs 10/- each & to determine "Relevant Date" for the purpose said issue price for the Preferential Issue of the warrants. |
| Jul 28, 2008 | Quarterly Results | - |
| May 13, 2008 | Audited Results & Final Dividend | - |
| Jan 28, 2008 | Quarterly Results | - |
| Oct 30, 2007 | Quarterly Results | - |
| Jul 30, 2007 | Quarterly Results | - |
| May 18, 2007 | Audited Results & Final Dividend | Has not recommended any final dividend. |
| Mar 12, 2007 | Interim Dividend | - |
| Jan 22, 2007 | Quarterly Results | - |
| Oct 19, 2006 | Quarterly Results | - |
| Jul 31, 2006 | Quarterly Results | - |
| May 10, 2006 | Accounts & Dividend | - |
| Jan 27, 2006 | Quarterly Results | - |
| Nov 08, 2005 | Quarterly Results & Half Yearly Results | - |
| Jul 29, 2005 | Quarterly Results & Accounts | (Revised) |
| May 05, 2005 | Others | Board has decided to acquire controlling stake in Suyash Laboratories Ltd (Suyash) thereby making it 51% subsidiary of the Company subject to necessary approvals from appropriate authority. |
| Apr 25, 2005 | Accounts, Qtr Results & F. Dividend | - |
| Apr 08, 2005 | Allotment of Unsecured FCCB's | Board has allotted 12750 Unsecured Foreign Currency Convertible Bonds (FCCBs) of US$ 1000 each aggregating to US$ 12,750,000 (US Dollar Twelve Million Seven Hundred Fifty Thousand Only). |
| Jan 21, 2005 | Quarterly Results | - |
| Dec 31, 2004 | To issue securities like FCCB's | Proposal to issue/offer securities like Foreign Currency Convertible Bonds (FCCB) and/or Equity Shares (through Depository Receipt Mechanism) and/or Fully Convertible Debentures. |
| Oct 29, 2004 | Quarterly Results | - |
| Jul 28, 2004 | Accounts | - |
| Apr 23, 2004 | Accounts & Final Dividend | - |
| Jan 21, 2004 | Quarterly Results | - |
| Oct 31, 2003 | Interim Dividend & Quarterly Results | (Revised) |
| Jul 21, 2003 | Quarterly Results | - |
| Apr 23, 2003 | Final Dividend & Accounts | - |
| Jan 20, 2003 | Quarterly Results | - |
| Oct 28, 2002 | Accounts & Buy Back of Shares | - |
| Jul 19, 2002 | Quarterly Results | - |
| May 10, 2002 | Final Dividend | - |
| Apr 17, 2002 | Dividend & Quarterly Results | - |
| Mar 09, 2002 | Interim Dividend | (Cancelled) |
| Jan 18, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Interim Dividend & Half Yearly Results | - |
| Jul 18, 2001 | Quarterly Results | - |
| Apr 18, 2001 | Accounts & Dividend | Dividend announced on 11/04/2001 |
| Jan 22, 2001 | Quarterly Results | - |
| Oct 18, 2000 | Quarterly Results | - |
| Apr 18, 2000 | Accounts | - |
| Mar 28, 2000 | 2nd Interim Dividend | - |
| Jan 28, 2000 | Quarterly Results | - |
| Oct 27, 1999 | Quarterly Results | - |
| Jul 30, 1999 | Quarterly Results | - |
| Apr 29, 1999 | Quarterly Results | - |
| Jan 29, 1999 | Quarterly Results | - |
| Jan 22, 1999 | Revised | - |
| Jan 20, 1999 | Quarterly Results | - |
| Oct 30, 1998 | Quarterly Results | - |
| Jul 20, 1998 | Quaterly Results | - |
| May 05, 1998 | Accounts & Dividend | - |
| Nov 26, 1997 | Half Yearly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Sep 30, 2020 | 3:1 | 2020-10-01 |
| Mar 24, 2015 | 1:1 | 2015-03-25 |
30 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating
26 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Financial Results
25 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Q2 and H1 FY25 Earning concall transcript
25 Oct 2024
Here's why Aarti Drugs shares fell 4% on October 25, more details here
The fall in Aarti Drugs share price came after the company reported a weak set of September quarter (Q2FY25) earnings.
25 Oct 2024
H1FY25 & Q2FY25 Result Announced for Aarti Drugs Ltd.
Pharmaceuticals company Aarti Drugs announced H1FY25 & Q2FY25 results Q2FY25 Standalone Financial Highlights: Revenue stood at Rs 543.1 crore as against Rs 577.5 crore, down by 6% YoY. Standalone business contributed ~89% to the consolidated revenue for the quarter. ~66% of the revenues came from the domestic market and ~34% from the exports market. Within the API business, the antibiotic therapeutic category contributed ~40%, anti-diabetic ~18%, antiprotozoal ~17%, anti-inflammatory ~10%, antifungal ~10% and the rest contributed ~4% to total API sales Q2FY25 Consolidated Financial Highlights: Revenue stood at Rs 599.8 crore as against Rs 642.2 crore, a decline of 7% YoY. This is on account of lower realizations stemming from negative rate variance and subdued market demand in the API business. EBITDA stood at Rs 68.5 crore as against Rs 77.1 crore, a decline of 11% YoY. EBITDA Margin (%) stood at 11.5%. PAT stood at Rs 35.0 crore as against Rs 39.6 crore, a decline of 12% YoY. PAT Margin (%) stood at 5.8% H1FY25 Consolidated Financial Highlights: Revenue stood at Rs 1,156.3 crore as against Rs 1,303.9 crore, a decline of 11% YoY. EBITDA stood at Rs 134.6 crore as against Rs 161.8 crore, a decline of 17% YoY. EBITDA Margin (%) stood at 11.7%. PAT stood at Rs 68.2 crore as against Rs 87.6 crore, a decline of 22% YoY. PAT Margin (%) stood at 5.9% Adhish Patil, CFO & COO, of Aarti Drugs said: “During Q2FY25, we have seen a drop in revenues and profitability on a year-on-year basis mainly due to lower realizations stemming from negative rate variance and subdued market demand in the API business. The volumes have remained flattish on a YoY basis whereas we have seen a growth of 10% from the last quarter. Since Q1, the prices have stabilized, and volumes have grown which has led to a growth of 8% in revenues on a QoQ basis. We expect pricing to improve going ahead. Formulation segment revenue stood at Rs 65.6 crore for the quarter, with exports contribution of ~53%. In H1FY25 revenue stood at Rs 136.6 crore. The greenfield project at Sayakha, Gujarat for Speciality Chemicals is expected to commence in this quarter. With this, the operating leverage is expected to kick in from the second half of the year with improved capacity utilization. The production of Salicylic Acid has commenced and currently we are producing 100 tonnes per month. There have been certain teething issues, and we expect to ramp up the production to 300+ tonnes by end of October’24. In total we will have sequential ramp up of capacity to 1,800 tonnesthroughout FY25 & FY26. During H1 FY25, the Company has incurred Capex of ~Rs 90 crore mainly towards capacity expansion, backward integration and new product launches. We anticipate a total Capex of ~Rs 200 crore for the full year. This Capex would we mainly through internal accruals and partly through term loans. The Pharma API manufacturing industry is constantly evolving, and we are committed to staying ahead of the curve. We continue to expand our capabilities and enhance our offerings to meet the ever-changing needs of our customeRs We also plan to invest in new technologies and equipment that will help us streamline our processes and improve efficiency.” Result PDF
24 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q2 and FY25 Investor Presentation
24 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Q2 and H1 FY25 Business and Financial Performance
24 Oct 2024
AARTI DRUGS LTD. - 524348 - Financial Results For The Quarter And Half Year Ended September 30, 2024
Financial Results for the quarter and half year ended September 30, 2024
18 Oct 2024
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate
17 Oct 2024
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earning conference call
